← United States · Coverage record
US · SEC FORM 4
Denali Therapeutics Inc.
DNLI · Nasdaq · CIK 0001714899 · Healthcare · Biotechnology
INSIDER SIGNAL
0 qualifying P purchase groups
in the current 180-day scoring window
14 Form 4 transaction lines observed in the same window
5 sales · 9 option, withholding, award, gift or other lines
WHY NO ACTIVE SIGNAL?
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Purchase breadth, concentration & cluster buying
These modules activate when qualifying purchases enter the 180-day research window.
Insider activity timeline
Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.
Showing the six most active owners; 5 additional owner(s) remain in Form 4 evidence.
SIGNAL HISTORY
Scores are archived only when the company qualifies for a published US buy-signal snapshot.—
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.
Short interest
Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.
- Shares short
- 15,463,975
- Previous report
- 17,139,415
- Avg daily volume
- 2,023,714
- Days to cover
- 7.6
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
No qualifying code P equity purchase is present in the local Form 4 history.
Form 4 evidence
19 transaction lines in the latest 365-day window; 526 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-09-04 | Chin Peter Scott | Sale (S) | Common Stock | 1,654 | USD 22.29 | USD 36,868 | SEC filing ↗ |
| 2026-09-02 | Thornberry Nancy | Sale (S) | Common Stock | 11,439 | USD 22.90 | USD 261,929 | SEC filing ↗ |
| 2026-09-01 | Schuth Alexander O. | Sale (S) | Common Stock | 2,768 | USD 23.44 | USD 64,882 | SEC filing ↗ |
Show recent Form 4 evidence (18 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-09-04 | Chin Peter Scott | Sale (S) | Common Stock | 1,654 | USD 22.29 | USD 36,868 | SEC filing ↗ |
| 2026-09-02 | Thornberry Nancy | Sale (S) | Common Stock | 11,439 | USD 22.90 | USD 261,929 | SEC filing ↗ |
| 2026-09-01 | Schuth Alexander O. | Sale (S) | Common Stock | 2,768 | USD 23.44 | USD 64,882 | SEC filing ↗ |
| 2026-08-12 | Watts Ryan J. | Gift (G) | Common Stock | 32,220 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-08-11 | Schuth Alexander O. | Sale (S) | Common Stock | 2,857 | USD 25.07 | USD 71,625 | SEC filing ↗ |
| 2026-06-03 | Van Hauwermeiren Timothy | Award / grant (A) | Common Stock | 6,408 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-06-03 | Thornberry Nancy | Award / grant (A) | Common Stock | 6,408 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-06-03 | Schenkein David P | Award / grant (A) | Common Stock | 6,408 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-06-03 | Krognes Steve E. | Award / grant (A) | Common Stock | 6,408 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-06-03 | Klein Peter S | Award / grant (A) | Common Stock | 6,408 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-06-03 | FLATLEY JAY T | Award / grant (A) | Common Stock | 6,408 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-06-03 | Cook Jennifer E. | Award / grant (A) | Common Stock | 6,408 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-06-03 | 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP | Award / grant (A) | Common Stock | 6,408 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-01-06 | Watts Ryan J. | Sale (S) | Common Stock | 35,198 | USD 16.50 | USD 580,767 | SEC filing ↗ |
| 2026-01-06 | Schuth Alexander O. | Sale (S) | Common Stock | 17,218 | USD 16.50 | USD 284,097 | SEC filing ↗ |
| 2026-01-03 | Watts Ryan J. | Award / grant (A) | Common Stock | 78,960 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-01-03 | Schuth Alexander O. | Award / grant (A) | Common Stock | 57,700 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2025-11-04 | Van Hauwermeiren Timothy | Award / grant (A) | Common Stock | 10,632 | USD 0.00 | USD 0 | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-19 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | DNLI |
| CIK | 0001714899 |
| Sector | Healthcare |
| Industry | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| Exchange | Nasdaq |
Data coverage
| Local Form 4 history | 526 transaction lines from 2020-02-07 to 2026-09-04 0 P purchase lines · 383 S sale lines · 143 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.